"You're going to probably
see, potentially, drug manufacturers that are willing to kind of step into this
and work with the PBMs — and of course their related health entities — to
administer these types of more complex systems."
— Ashraf
Shehata, a principal in KPMG's health care life sciences advisory practice,
talked with AIS's RADAR on
Drug Benefits about why PBMs are increasingly focused on high-touch
care management programs.
No comments:
Post a Comment